Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-08-26

Clinical Trial Results: Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris [Phase 2]

View source ↗

Summary

Phase 2 trial results of deucravacitinib (BMS-986165) for pityriasis rubra pilaris have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Pityriasis Rubra Pilaris | Phase 2 | Status: COMPLETED | Results posted: 2026-08-26